Navigation Links
Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout
Date:11/24/2008

DEERFIELD, Ill., and OSAKA, Japan, Nov. 24 /PRNewswire/ -- Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., announced today that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended that the FDA approve febuxostatfor the treatment of hyperuricemia in patients with gout. The vote was 12 to zero in favor of approval, with one panel member abstaining. The vote followed presentations by Takeda Global Research & Development Center, Inc., the FDA, and invited guest speakers. If approved in the United States by the FDA, febuxostat will be the first new treatment for the management of hyperuricemia associated with gout in more than 40 years.

The FDA will review the current new drug application for febuxostat and make its approval decision. The FDA's decision may or may not follow the Committee's recommendation.

"Today's vote by the Arthritis Advisory Committee, recommending approval of febuxostat for the treatment of hyperuricemia in patients with gout, is a positive step in bringing this new treatment to market," said Nancy Joseph-Ridge, MD, president, Takeda Global Research & Development, Inc., U.S. "Takeda is committed to developing innovative therapies that fulfill unmet treatment needs, and we believe febuxostat will represent an important new option for patients who suffer the debilitating effects of gout. In the coming months, we will work with the FDA to complete their review, including the design of post-marketing studies."

Febuxostat is a potent non-purine, selective inhibitor of xanthine oxidase, which was studied for its ability to lower levels of serum uric acid in patients with hyperuricemia associated with gout. Hyperuricemia, elevated uric acid levels in the body, is associated with gout, a painful type of arthritis. In clinical trials, febuxostat 40 mg and 80 mg were shown to be effective treatments for the management of hyperuricemia associated with gout. Both doses were well tolerated and required no dose adjustments in patients with renal impairment. The most commonly reported adverse events were upper respiratory tract infections, musculoskeletal and connective tissue signs and symptoms, and diarrhea.

About Gout and Uric Acid

Uric acid is an end-product created when the body breaks down naturally occurring substances called purines. Hyperuricemia occurs when this process results in elevated uric acid levels, either through overproduction or underexcretion of uric acid or a combination of the two. Hyperuricemia is a precursor to gout; the higher a person's urate level, the greater the risk for developing gout.

Gout is the most common inflammatory arthritis in men over age 40. According to the National Health and Nutrition Examination Survey III 1988-1994, an estimated 5.1 million Americans suffer from gout. It is a chronic condition characterized by attacks, or "flares," marked by intense pain, redness, swelling, and heat in the affected joint. These symptoms are the result of an acute inflammatory response to the presence of crystallized uric acid in the joint(s). As the disease progresses, these attacks may become more frequent and patients may develop large deposits of crystallized uric acid visible under the skin, known as tophi, that can eventually lead to complications including pain, soft tissue damage and deformity, as well as joint destruction and nerve compression syndromes such as carpal tunnel syndrome.

Takeda Pharmaceutical Company Limited

Takeda, located in Osaka, Japan, is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan, and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, www.takeda.com.

Takeda Pharmaceuticals North America, Inc.and Takeda Global Research & Development Center, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia and gastroenterology treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, cardiovascular disease, oncology, gastroenterology, neurology, rheumatology and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about these Takeda companies, visit www.tpna.com.


'/>"/>
SOURCE Takeda Pharmaceutical Company Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
2. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
3. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
4. ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
5. Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period
6. Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis
7. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
8. New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis
9. Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis
10. Orthokine Treatment is Effective for Knee Arthritis, Even After Two Years
11. Pediatric Researchers Find Possible Master Switch Gene in Juvenile Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... The global dental bone graft ... CAGR of 10.6% within a forecast period from 2014 ... in 2013. Owing to favorable factors at play in ... by the end of this forecast period, i.e. 2020. ... representation in a research report published by Transparency Market ...
(Date:5/31/2016)... , May 31, 2016 ... and Annotate Content From Elsevier,s ScienceDirect Database ... scientific, technical and medical information products and services, ... Berlin -based scientific collaboration platform PaperHive to enable ... over 12 million articles on ScienceDirect , ...
(Date:5/31/2016)... May 31, 2016 , Isansys  Lifecare, ... its Patient Status Engine wireless patient monitoring platform, as it ... Germany , Scotland and ... 2 nd generation system, launched earlier this year, is now ... , , This new technology significantly enhances ...
Breaking Medicine Technology:
(Date:5/31/2016)... York, New York (PRWEB) , ... May 31, 2016 , ... ... effects research to provide the best accessories to avoid excessive Smartphone radiation implicated in ... of the study released on the bioRxiv preprint server on May 26th ...
(Date:5/31/2016)... Barbara, CA (PRWEB) , ... May 31, 2016 , ... Throughout the day, adults often ... for sustained motivation and awareness, but what they could be reaching for instead is a ... tea plants that are grown in Japan. This sacred tea is harvested from early June ...
(Date:5/31/2016)... ... May 31, 2016 , ... St. Joseph Medical Center ... information exchange, which enables physicians at SJMC’s two hospital campuses, downtown and in ... organizations in the exchange. SJMC’s membership in the health information exchange underscores the ...
(Date:5/31/2016)... , ... May 31, 2016 , ... DDL, Inc. announced ... Association for Laboratory Accreditation (A2LA) to include ISO 594-1 and ISO 594-2 testing for ... of achieving a leak-free connection between two medical devices (e.g. a syringe and hypodermic ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... The successful ... model in their laboratories as well. However, laboratories have different challenges compared to manufacturing ... of lean operations in the lab, METTLER TOLEDO has developed the Lean Lab ...
Breaking Medicine News(10 mins):